Paulo R Shiroma1,2, Mario Renato Velit-Salazar3, Yelena Vorobyov4. 1. Mental Health Service Line, Minneapolis VA Medical Center, One Veterans Drive 116-A, Minneapolis, MN, 55417, USA. paulo.shiroma@va.gov. 2. Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA. paulo.shiroma@va.gov. 3. Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA. 4. Mental Health Service Line, Minneapolis VA Medical Center, One Veterans Drive 116-A, Minneapolis, MN, 55417, USA.
Abstract
BACKGROUND AND OBJECTIVE: Ketamine, a noncompetitive, high-affinity antagonist of the N-methyl-D-aspartate type glutamate receptor, has been investigated for its high efficacy and rapid antidepressant effect and, more recently, for its potential utility in post-traumatic stress disorder (PTSD). The proposal that ketamine's antidepressant and anti-suicidal mechanism may be in part due to its procognitive effect contrasts with the well-established decreased performance on spatial working memory and pattern recognition memory among long-term frequent users. We aimed to review the neurocognitive effects of subanesthetic doses of intravenous ketamine in pharmacological studies among healthy subjects and patients with PTSD or depression. METHODS: We included studies in English, among healthy adults, or with PTSD or unipolar or bipolar depression where the primary or secondary cognitive outcomes were measured by means of validated neuropsychological test. We excluded studies that reported the use of ketamine only in combination with other drugs or psychotherapy, or studies investigating emotion-laden cognitive functions. RESULTS: Ketamine administration among patients with depression and possibly with PTSD does not show significant impairment of cognitive functions in the short-term, in contrast with the immediate altered cognitive dysfunction found in healthy subjects. The potential procognitive effects of ketamine seem more pronounced in cognitive domains of executive function, which is in line with the putative molecular, cellular, and synaptic mechanisms of ketamine's therapeutic action. CONCLUSIONS: The potential procognitive effect of ketamine deserves further exploration. Whether ketamine has transient or sustained neurocognitive benefits beyond its antidepressant effects is unknown. Improved cognition by ketamine might be used to facilitate psychotherapy interventions for PTSD and depression.
BACKGROUND AND OBJECTIVE: Ketamine, a noncompetitive, high-affinity antagonist of the N-methyl-D-aspartate type glutamate receptor, has been investigated for its high efficacy and rapid antidepressant effect and, more recently, for its potential utility in post-traumatic stress disorder (PTSD). The proposal that ketamine's antidepressant and anti-suicidal mechanism may be in part due to its procognitive effect contrasts with the well-established decreased performance on spatial working memory and pattern recognition memory among long-term frequent users. We aimed to review the neurocognitive effects of subanesthetic doses of intravenous ketamine in pharmacological studies among healthy subjects and patients with PTSD or depression. METHODS: We included studies in English, among healthy adults, or with PTSD or unipolar or bipolar depression where the primary or secondary cognitive outcomes were measured by means of validated neuropsychological test. We excluded studies that reported the use of ketamine only in combination with other drugs or psychotherapy, or studies investigating emotion-laden cognitive functions. RESULTS: Ketamine administration among patients with depression and possibly with PTSD does not show significant impairment of cognitive functions in the short-term, in contrast with the immediate altered cognitive dysfunction found in healthy subjects. The potential procognitive effects of ketamine seem more pronounced in cognitive domains of executive function, which is in line with the putative molecular, cellular, and synaptic mechanisms of ketamine's therapeutic action. CONCLUSIONS: The potential procognitive effect of ketamine deserves further exploration. Whether ketamine has transient or sustained neurocognitive benefits beyond its antidepressant effects is unknown. Improved cognition by ketamine might be used to facilitate psychotherapy interventions for PTSD and depression.
Authors: Yena Lee; Kahlood Syeda; Nadia A Maruschak; Danielle S Cha; Rodrigo B Mansur; Ida K Wium-Andersen; Hanna O Woldeyohannes; Joshua D Rosenblat; Roger S McIntyre Journal: J Clin Psychopharmacol Date: 2016-02 Impact factor: 3.153
Authors: Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji Journal: Arch Gen Psychiatry Date: 2006-08
Authors: Robin L Aupperle; Carolyn B Allard; Erin M Grimes; Alan N Simmons; Taru Flagan; Michelle Behrooznia; Shadha H Cissell; Elizabeth W Twamley; Steven R Thorp; Sonya B Norman; Martin P Paulus; Murray B Stein Journal: Arch Gen Psychiatry Date: 2012-04
Authors: Vanina Popova; Ella J Daly; Madhukar Trivedi; Kimberly Cooper; Rosanne Lane; Pilar Lim; Christine Mazzucco; David Hough; Michael E Thase; Richard C Shelton; Patricio Molero; Eduard Vieta; Malek Bajbouj; Husseini Manji; Wayne C Drevets; Jaskaran B Singh Journal: Am J Psychiatry Date: 2019-05-21 Impact factor: 18.112
Authors: James W Murrough; Dan V Iosifescu; Lee C Chang; Rayan K Al Jurdi; Charles E Green; Andrew M Perez; Syed Iqbal; Sarah Pillemer; Alexandra Foulkes; Asim Shah; Dennis S Charney; Sanjay J Mathew Journal: Am J Psychiatry Date: 2013-10 Impact factor: 18.112
Authors: Zhen Yang; Desmond J Oathes; Kristin A Linn; Steven E Bruce; Theodore D Satterthwaite; Philip A Cook; Emma K Satchell; Haochang Shou; Yvette I Sheline Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-12-28